FDA grants EUA for Eli Lilly treatment in conjunction with Remdesivir
The Food and Drug Administration has granted Emergency Use Approval for baricitinib, a treatment for Covid-19 developed jointly by Eli Lilly and Incyte, in combination with Gilead Sciences's remdesivir.
EUA has been granted for use in adult and pediatric patients who require supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation.
In the case of Eli Lilly, it marked the second EUA obtained from the same drug regulator for one of its Covid-19 treatments.
On 9 November, the FDA granted EUA for Eli's neutralising antibody treatment for Covid-19 in high-risk non-hospitalised patients.
A clinical trial to determine baricitinib's efficacy and safety as a treatment for COVID-19 was ongoing.
As of 1422 GMT, shares of Eli Lilly were little changed, advancing 0.27% to $143.8, alongside a 0.69% gain for Incyte to $82.25.
Important Legal Notice about News Sources: Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news articles and we may not share the views of the author. We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.